Skip to main content

Advertisement

SpringerLink
Log in

Tumor-Derived Membrane Vesicles from the IL-2 Overexpression Melanoma Cells Affect on the Expression of Surface Markers of Human Peripheral Blood Mononuclear Cells In Vitro

  • Published:
BioNanoScience Aims and scope Submit manuscript

Abstract

Nowadays, immunotherapy, in particular immunotherapeutic vaccines, is a promising approach in the treatment of cancer which has already demonstrated its effectiveness. Extracellular vesicles (EVs), which are capable of delivering biologically active agents to the cells, can be a promising candidate for such vaccines. M14 human melanoma cells were transduced with lentivirus encoding interleukin (IL)–2. Membrane vesicles from M14 cells expressing IL-2 were isolated using cytochalasin B. The interaction of membrane vesicles with human peripheral blood mononuclear cells has been analyzed. Activation of T cells was shown, as well as a decrease in the number of NK cells, after cultivation with tumor-derived vesicles. However, no cytotoxic activity of T cells after cultivation with tumor-derived vesicles was observed, which can be explained by their immunosuppressive properties. On the other hand, such vesicles can be a promising source of tumor-specific antigens for dendritic vaccines. Therefore, further studies are required in view of the possible use of tumor-derived vesicles as a target antigen for dendritic cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

The authors confirm that all relevant data used to support the findings of this study are included within the article.

References

  1. Shupp, A. B., Kolb, A. D., & Bussard, K. M. (2020). Novel techniques to study the bone-tumor microenvironment. Advances in Experimental Medicine and Biology, 1225, 1–18.

    Article  Google Scholar 

  2. Chulpanova, D. S., et al. (2018). Therapeutic prospects of extracellular vesicles in cancer treatment. Frontiers in Immunology, 9, 1534.

    Article  Google Scholar 

  3. Mathieu, M., et al. (2019). Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nature Cell Biology, 21(1), 9–17.

    Article  Google Scholar 

  4. Kawamoto, T., et al. (2012). Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis. PLoS ONE, 7(3), e34045.

    Article  Google Scholar 

  5. Wang, Y., et al. (2020). Tumor-derived EV-encapsulated miR-181b-5p induces angiogenesis to foster tumorigenesis and metastasis of ESCC. Mol Ther Nucleic Acids, 20, 421–437.

    Article  Google Scholar 

  6. Andrade, L. N. S., et al. (2019). Extracellular vesicles shedding promotes melanoma growth in response to chemotherapy. Science and Reports, 9(1), 14482.

    Article  MathSciNet  Google Scholar 

  7. Robbins, P. D., & Morelli, A. E. (2014). Regulation of immune responses by extracellular vesicles. Nature Reviews Immunology, 14(3), 195–208.

    Article  Google Scholar 

  8. Prada, I., & Meldolesi, J. (2016). Binding and fusion of extracellular vesicles to the plasma membrane of their cell targets. International Journal of Molecular Sciences, 17(8), 1296.

    Article  Google Scholar 

  9. Choudhry, H., et al. (2018). Prospects of IL-2 in cancer immunotherapy. BioMed Research International, 2018, 9056173.

    Article  Google Scholar 

  10. Chulpanova, D. S., et al. (2021). Cytochalasin B-induced membrane vesicles from human mesenchymal stem cells overexpressing IL2 are able to stimulate CD8(+) T-killers to kill human triple negative breast cancer cells. Biology (Basel), 10(2), 141.

    Google Scholar 

  11. Davis, L. E., Shalin, S. C., & Tackett, A. J. (2019). Current state of melanoma diagnosis and treatment. Cancer Biology & Therapy, 20(11), 1366–1379.

    Article  Google Scholar 

  12. Overwijk, W. W., Tagliaferri, M. A., & Zalevsky, J. (2021). Engineering IL-2 to give new life to T cell immunotherapy. Annual Review of Medicine, 72, 281–311.

    Article  Google Scholar 

  13. Tarhini, A. A., et al. (2007). Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. Journal of Clinical Oncology, 25(25), 3802–3807.

    Article  Google Scholar 

  14. Pol, J. G., et al. (2020). Effects of interleukin-2 in immunostimulation and immunosuppression. Journal of Experimental Medicine, 217(1), e20191247.

    Article  Google Scholar 

  15. Jen, E. Y., et al. (2012). IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells. Melanoma Research, 22(1), 19–29.

    Article  Google Scholar 

  16. Wrangle, J. M., et al. (2018). IL-2 and beyond in cancer immunotherapy. Journal of Interferon and Cytokine Research, 38(2), 45–68.

    Article  Google Scholar 

  17. Schwartz, R. N., Stover, L., & Dutcher, J. P. (2002). Managing toxicities of high-dose interleukin-2. Oncology (Williston Park N.Y.), 16(11 Suppl 13), 11–20.

    Google Scholar 

  18. Poindexter, N. J., et al. (2005). Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. Journal of Leukocyte Biology, 78(3), 745–752.

    Article  Google Scholar 

  19. Wahlgren, J., et al. (2012). Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Research, 40(17), e130.

    Article  Google Scholar 

  20. Zhao, S., et al. (2020). Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. Journal of Hematology & Oncology, 13(1), 156.

    Article  Google Scholar 

  21. Hu, J. L., et al. (2019). CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Molecular Cancer, 18(1), 91.

    Article  Google Scholar 

  22. Zhou, C., et al. (2021). Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. Molecular Therapy, 29(4), 1512–1528.

    Article  Google Scholar 

  23. Sharma, P., et al. (2020). Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Science and Reports, 10(1), 92.

    Article  Google Scholar 

  24. Chen, G., et al. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 560(7718), 382–386.

    Article  Google Scholar 

  25. Li, Q., et al. (2021). Tumor-derived extracellular vesicles: Their role in immune cells and immunotherapy. International Journal of Nanomedicine, 16, 5395–5409.

    Article  Google Scholar 

  26. Zhao, J., et al. (2019). Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers (Basel), 11(6), 874.

    Article  Google Scholar 

Download references

Funding

This research was funded by the Russian Science Foundation grant no. 22–24-20018 and Kazan Federal University Strategic Academic Leadership Program.

Author information

Authors and Affiliations

  1. Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia

    Ivan Yu Filin, Kristina V. Kitaeva, Daria S. Chulpanova, Albert A. Rizvanov, Elvira R. Akhmetzyanova & Valeriya V. Solovyeva

Authors
  1. Ivan Yu Filin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristina V. Kitaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daria S. Chulpanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albert A. Rizvanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elvira R. Akhmetzyanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Valeriya V. Solovyeva
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: F.I.Y., K.K.V., and V.V.S. Methodology: F.I.Y., K.K.V., and V.V.S. Formal analysis: F.I.Y. and K.K.V. Investigation: D.S.C. (flow cytometry analysis) and E.R.A. (confocal microscopy). Writing—original draft preparation: F.I.Y. and K.K.V. Writing—review and editing: V.V.S. and D.S.C. Visualization: K.K.V. Supervision: A.A.R. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Valeriya V. Solovyeva.

Ethics declarations

Research Involving Human and Animals Statement

An informed consent was obtained from all subjects involved in the study. All manipulations were carried out in accordance with approved ethical standards and current legislation (the protocol was approved by the Committee on Biomedical Ethics of Kazan Federal University (No. 3, 03/23/2017)). This study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants included in the study.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Filin, I.Y., Kitaeva, K.V., Chulpanova, D.S. et al. Tumor-Derived Membrane Vesicles from the IL-2 Overexpression Melanoma Cells Affect on the Expression of Surface Markers of Human Peripheral Blood Mononuclear Cells In Vitro. BioNanoSci. 13, 81–87 (2023). https://doi.org/10.1007/s12668-022-01044-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12668-022-01044-3

Keywords

Search

Navigation